Fatal immune checkpoint inhibitor-related pneumonitis following postoperative nivolumab administration in a patient with unclassifiable interstitial pneumonia and resected lung squamous cell carcinoma: A case report
This case highlights the potentially fatal risk of postoperative nivolumab therapy in patients with pre-existing ILD, even in the setting of unclassifiable interstitial pneumonia. Careful risk-benefit assessment is warranted when considering adjuvant immune checkpoint inhibitors in this population.
Authors
- Kenzo Hiroshima (ORCID: https://orcid.org/0000-0002-0865-0820)
- Yasuo Sekine (ORCID: https://orcid.org/0000-0001-6111-5715)
- Eitetsu Koh (ORCID: https://orcid.org/0009-0004-8983-9239)
Institutions
- Tokyo Women's Medical University (JP)
- Tokyo Women's Medical University Yachiyo Medical Center
Publication Details
- Journal
- Respiratory Medicine Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.rmcr.2025.102294
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00